A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

• Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes

• Intraocular Pressure (IOP) of at least 22 mmHg and not more than 30 mmHg in either eye at 8 AM after discontinuing previous glaucoma treatment

• Visual acuity correctable to 20/100 or better in each eye.

Exclusion Criteria:

• Closed/barely open anterior chamber angle or a history of acute angle closure in either eye.

• Diagnosis of a clinically significant or progressive retinal disease (eg, diabetic retinopathy, macular degeneration) in either eye.

• Advanced glaucoma or a history of severe central visual field loss in either eye.

• History of ocular surgery or trauma in either eye within 6 months of the screening visit.

• History of ocular infection, ocular inflammation, or laser surgery in either eye within 3 months of the screening visit.